A method to prepare a therapeutic balm is disclosed. A first phase solution is prepared in an oak barrel using a grain neutral spirit. The first phase is mixed for 10 minutes per day for a month to prepare a second phase solution. The second phase solution is filtered at least twice to prepare a filtrate. The filtrate and third phase components are mixed to prepare a third phase solution. The third phase solution is mixed with a distilled wine liquor to prepare a fourth phase solution. The fourth phase solution is mixed at least twice a day for a month to prepare a fifth phase solution. The fifth phase solution is mixed with cranberry juice, pomegranate juice, and raspberry juice to prepare a sixth phase solution. The sixth phase solution is stored in a ceramic bottle for a least six months at room temperature to prepare a therapeutic balm.

A method to prepare a therapeutic balm is disclosed. A first phase solution is prepared in an oak barrel using a grain neutral spirit. The first phase is mixed for 10 minutes per day for a month to prepare a second phase solution. The second phase solution is filtered at least twice to prepare a filtrate. The filtrate and third phase components are mixed to prepare a third phase solution. The third phase solution is mixed with a distilled wine liquor to prepare a fourth phase solution. The fourth phase solution is mixed at least twice a day for a month to prepare a fifth phase solution. The fifth phase solution is mixed with cranberry juice, pomegranate juice, and raspberry juice to prepare a sixth phase solution. The sixth phase solution is stored in a ceramic bottle for a least six months at room temperature to prepare a therapeutic balm.

The present invention patent application relates essentially to a supplement, the function of which is to enhance immunity, prevent various diseases and assist in therapeutic treatments of various diseases, said supplement being composed of: 100 mg of lipoic acid, 1 mg of astaxanthin, 10 mg of glutathione, 5 mg of resveratrol, 5 mg of lycopene, 50 mg of epigallocatechin, 300 mg of curcumin, 400 mg of quercetin, 10 mg of coenzyme Q1 and 100 mg of dry açaí extract; formulated with the intention of combining substances that serve functions of assisting in the treatment of various diseases, such as: lipoic acid, which helps in the prevention of liver damage from intoxication, and can be used as a coadjuvant for the treatment of liver cirrhosis due to alcoholism and a coadjuvant for the treatment of diabetes and cataracts.

The present invention patent application relates essentially to a supplement, the function of which is to enhance immunity, prevent various diseases and assist in therapeutic treatments of various diseases, said supplement being composed of: 100 mg of lipoic acid, 1 mg of astaxanthin, 10 mg of glutathione, 5 mg of resveratrol, 5 mg of lycopene, 50 mg of epigallocatechin, 300 mg of curcumin, 400 mg of quercetin, 10 mg of coenzyme Q1 and 100 mg of dry açaí extract; formulated with the intention of combining substances that serve functions of assisting in the treatment of various diseases, such as: lipoic acid, which helps in the prevention of liver damage from intoxication, and can be used as a coadjuvant for the treatment of liver cirrhosis due to alcoholism and a coadjuvant for the treatment of diabetes and cataracts.

The present invention patent application relates essentially to a supplement, the function of which is to enhance immunity, prevent various diseases and assist in therapeutic treatments of various diseases, said supplement being composed of: 100 mg of lipoic acid, 1 mg of astaxanthin, 10 mg of glutathione, 5 mg of resveratrol, 5 mg of lycopene, 50 mg of epigallocatechin, 300 mg of curcumin, 400 mg of quercetin, 10 mg of coenzyme Q1 and 100 mg of dry açaí extract; formulated with the intention of combining substances that serve functions of assisting in the treatment of various diseases, such as: lipoic acid, which helps in the prevention of liver damage from intoxication, and can be used as a coadjuvant for the treatment of liver cirrhosis due to alcoholism and a coadjuvant for the treatment of diabetes and cataracts.

The present disclosure describes a novel anhydrous topical pharmaceutical composition comprised of marine oil, such as fish oil or algae oil; vegetable oil having a an omega3 fat content greater than 9 wt %, such as hempseed oil, canola oil, flax seed oil, or cannabidiol; monolaurin, cetyl esters or wax; and medium chain triglycerides (“MCT”), and optionally fish collagen. The composition is useful for treating wounds, burns and skin conditions.

The present disclosure describes a novel anhydrous topical pharmaceutical composition comprised of marine oil, such as fish oil or algae oil; vegetable oil having a an omega3 fat content greater than 9 wt %, such as hempseed oil, canola oil, flax seed oil, or cannabidiol; monolaurin, cetyl esters or wax; and medium chain triglycerides (“MCT”), and optionally fish collagen. The composition is useful for treating wounds, burns and skin conditions.

A composition of isopropyl or ethyl alcohol, Cetylpyridinium Chloride and essential oils that enable the composition to have a prolonged antimicrobial effect by reducing the normal rate of alcohol dehydration, reducing toxicity and increasing duration of efficacy with proper application to oral cavity, oropharynx and directly pharyngeal tonsils.

A composition of isopropyl or ethyl alcohol, Cetylpyridinium Chloride and essential oils that enable the composition to have a prolonged antimicrobial effect by reducing the normal rate of alcohol dehydration, reducing toxicity and increasing duration of efficacy with proper application to oral cavity, oropharynx and directly pharyngeal tonsils.

A composition of isopropyl or ethyl alcohol, Cetylpyridinium Chloride and essential oils that enable the composition to have a prolonged antimicrobial effect by reducing the normal rate of alcohol dehydration, reducing toxicity and increasing duration of efficacy with proper application to oral cavity, oropharynx and directly pharyngeal tonsils.